The sharp rise in the share price comes on the back of high trading volumes, with over 35 lakh shares worth around Rs 640 ...

Sundar Kewat of Ashika Institutional Equity and Avinash Gorakshakar of Profitmart Securities provide insights.

Wockhardt extended its winning streak for the third straight session, drawing strong investor interest with trading volumes ...

Habil Khorakiwala has seen more than his fair share of ups and downs in the nearly 60 years since he founded the Mumbai-based pharmaceuticals company Wockhardt in 1967. But even so, the closure of ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

The company is eyeing global market worth over $7 billion. Zaynich, a new antibiotic targeting the most severe of multi-drug resistant infections, has completed its global Phase III clinical study wit ...

Drugmaker Wockhardt on Friday said that it has filed for regulatory approval of its Zaynich with the Drug Controller General ...

Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a ...

Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated ...

Mumbai: A 32-year-old man in Mumbai got his hand reconstructed after it was crushed in a sugarcane squeezer. Although the ...

Wockhardt plans to trim $12 million in annual expenses by restructuring its U.S. business and shuttering its Morton Grove, Illinois, manufacturing facility. As part of the U.S. restructuring ...